@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix RNA: . @prefix hgnc: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:7176; a RNA: . sub:_2 rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject schem:Tetradecanoylphorbol%20acetate; a rdf:Statement . sub:_3 occursIn: obo:UBERON_0004237, species:9606; rdf:object sub:_2; rdf:predicate belv:decreases; rdf:subject schem:15-deoxy-D12%2C14-prostaglandin%20J2; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:\"15-deoxy-D12,14-prostaglandin J2\") -| (a(SCHEM:\"Tetradecanoylphorbol acetate\") -> r(HGNC:MMP9))", "a(SCHEM:\"Tetradecanoylphorbol acetate\") -> r(HGNC:MMP9)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Treatment of VSMCs with the PPARgamma ligands troglitazone and the naturally occurring 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) decreased phorbol 12-myristate 13-acetate-induced MMP-9 mRNA and protein levels, as well as MMP-9 gelatinolytic activity in the supernatants in a concentration-dependent manner. "; prov:wasQuotedFrom pubmed:9831704 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:9831704; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:34:18.922+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }